Serum C-X-C motif chemokine ligand 14 levels are associated with serum C-peptide and fatty liver index in type 2 diabetes mellitus patients.
Adiponectin
/ blood
Age Factors
Aged
Alanine Transaminase
/ blood
Biomarkers
/ blood
Body Mass Index
C-Peptide
/ blood
Chemokines, CXC
/ blood
Cholesterol
/ blood
Diabetes Mellitus, Type 2
/ blood
Fatty Liver
/ blood
Female
Humans
Insulin Resistance
/ genetics
Intra-Abdominal Fat
Linear Models
Lipoproteins, LDL
/ blood
Liver Function Tests
Male
Middle Aged
Obesity
/ blood
Pulse Wave Analysis
Triglycerides
/ blood
Uric Acid
/ blood
Waist Circumference
/ genetics
C-X-C motif chemokine ligand 14
Hepatic steatosis
Insulin resistance
Journal
Journal of diabetes investigation
ISSN: 2040-1124
Titre abrégé: J Diabetes Investig
Pays: Japan
ID NLM: 101520702
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
22
09
2020
received:
15
03
2020
accepted:
11
10
2020
pubmed:
17
10
2020
medline:
10
11
2021
entrez:
16
10
2020
Statut:
ppublish
Résumé
Recent studies have suggested C-X-C motif chemokine ligand 14 (CXCL14), secreted from adipose tissue, to play an important role in the pathogenesis of metabolic syndrome. However, the clinical significance of CXCL14 in humans has not been elucidated. This study aimed to assess correlations between serum CXCL14 levels and clinical parameters in patients with type 2 diabetes mellitus. In total, 176 individuals with type 2 diabetes mellitus were recruited. Serum CXCL14 concentrations were determined by enzyme-linked immunosorbent assay. We examined the associations of serum CXCL14 levels with laboratory values, abdominal computed tomography image information, surrogate markers used for evaluating the pathological states of diabetes, obesity and atherosclerosis. Serum CXCL14 levels correlated positively with body mass index, waist circumference, subcutaneous and visceral fat areas, and serum alanine transaminase, uric acid, total cholesterol, low-density lipoprotein cholesterol, triglycerides and C-peptide (CPR) levels. In contrast, CXCL14 levels correlated inversely with age, pulse wave velocity and serum adiponectin levels. Multiple linear regression analysis showed serum levels of CPR (β = 0.227, P = 0.038) and the fatty liver index (β = 0.205, P = 0.049) to be the only parameters showing independent statistically significant associations with serum CXCL14 levels. Serum CXCL14 levels were independently associated with serum CPR and fatty liver index in patients with type 2 diabetes mellitus. In these patients, a high serum CPR concentration might reflect insulin resistance rather than β-cell function, because CXCL14 showed simple correlations with obesity-related parameters. Collectively, these data suggested that serum CXCL14 levels in type 2 diabetes patients might be useful predictors of elevated serum CPR and hepatic steatosis.
Identifiants
pubmed: 33063457
doi: 10.1111/jdi.13438
pmc: PMC8169342
doi:
Substances chimiques
Adiponectin
0
Biomarkers
0
C-Peptide
0
CXCL14 protein, human
0
Chemokines, CXC
0
Lipoproteins, LDL
0
Triglycerides
0
Uric Acid
268B43MJ25
Cholesterol
97C5T2UQ7J
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1042-1049Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K08523
Informations de copyright
© 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
Références
Trends Endocrinol Metab. 2017 Dec;28(12):855-867
pubmed: 29113711
Cardiovasc Diabetol. 2013 Jan 22;12:21
pubmed: 23339473
J Hepatol. 2018 Feb;68(2):305-315
pubmed: 29154965
J Endocr Soc. 2019 Jul 23;3(10):1847-1857
pubmed: 31555755
J Immunol. 2000 Sep 1;165(5):2588-95
pubmed: 10946286
PLoS One. 2017 Sep 18;12(9):e0184723
pubmed: 28922364
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
Cell Metab. 2018 Nov 6;28(5):750-763.e6
pubmed: 30122557
Cancer Manag Res. 2019 Dec 12;11:10435-10443
pubmed: 31849533
Br J Cancer. 2016 May 10;114(10):1117-24
pubmed: 27115465
BMJ Open Diabetes Res Care. 2020 Feb;8(1):
pubmed: 32107266
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
J Clin Invest. 2017 Jan 3;127(1):74-82
pubmed: 28045400
Diabet Med. 2009 Sep;26(9):847-54
pubmed: 19719704
J Biochem. 2012 May;151(5):469-76
pubmed: 22437940
Thorax. 2017 Sep;72(9):780-787
pubmed: 28250200
J Atheroscler Thromb. 2019 Dec 1;26(12):1045-1053
pubmed: 30880296
Exp Hematol. 2006 Aug;34(8):1101-5
pubmed: 16863917
Circ Res. 2007 Jul 6;101(1):27-39
pubmed: 17615379
J Dermatol. 2019 Jul;46(7):584-589
pubmed: 31087594
Eur J Pharmacol. 2011 Dec 5;671(1-3):120-7
pubmed: 21978833
Sci Rep. 2015 Mar 13;5:9083
pubmed: 25765541
Mol Cell Biol. 2007 Feb;27(3):983-92
pubmed: 17130243
PLoS Genet. 2007 Jun;3(6):e87
pubmed: 17542648
Nat Med. 2015 Apr;21(4):389-94
pubmed: 25774848
J Atheroscler Thromb. 2016 Oct 1;23(10):1178-1187
pubmed: 26961217
PLoS One. 2010 Apr 23;5(4):e10321
pubmed: 20428232
World J Gastroenterol. 2013 Jan 7;19(1):57-64
pubmed: 23326163
J Biol Chem. 2007 Oct 19;282(42):30794-803
pubmed: 17724031
J Inflamm (Lond). 2016 Jan 05;13:1
pubmed: 26733763
Biochem Biophys Res Commun. 2007 Dec 28;364(4):1037-42
pubmed: 17971304
Biochem Biophys Res Commun. 1999 Feb 24;255(3):703-6
pubmed: 10049774
Cytokine. 2018 Nov;111:500-504
pubmed: 29880273